Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C72H120N20O21S3.Tc |
| Molecular Weight | 1796.946 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[99Tc].CC(=NO)C(C)(C)NCCC(CCNC(=O)CCCC(=O)NCCCC[C@@H]1NC(=O)CSC[C@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N3)C(=O)NCCOCCOCCOCCNC(=O)COCC(N)=O)CCNC(C)(C)C(C)=NO
InChI
InChIKey=ORBUAXYWHYOTMA-HINGAUKESA-N
InChI=1S/C72H120N20O21S3.Tc/c1-45(91-108)71(3,4)82-26-21-47(22-27-83-72(5,6)46(2)92-109)20-25-77-58(95)19-12-18-57(94)76-23-11-10-16-50-65(103)89-54-42-115-116-43-55(90-67(105)52(37-62(99)100)85-59(96)38-81-63(101)49(86-68(54)106)17-13-24-80-70(74)75)69(107)87-51(36-48-14-8-7-9-15-48)66(104)88-53(41-114-44-61(98)84-50)64(102)79-29-31-111-33-35-112-34-32-110-30-28-78-60(97)40-113-39-56(73)93;/h7-9,14-15,47,49-55,82-83,108-109H,10-13,16-44H2,1-6H3,(H2,73,93)(H,76,94)(H,77,95)(H,78,97)(H,79,102)(H,81,101)(H,84,98)(H,85,96)(H,86,106)(H,87,107)(H,88,104)(H,89,103)(H,90,105)(H,99,100)(H4,74,75,80);/b91-45+,92-46+;/t49-,50-,51-,52-,53-,54-,55-;/m0./s1/i;1+1
| Molecular Formula | Tc |
| Molecular Weight | 98.9063 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C72H120N20O21S3 |
| Molecular Weight | 1698.04 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 6 |
| Optical Activity | UNSPECIFIED |
Maraciclatide Tc-99m is radiolabelled with technetium 99m cyclic peptide maraciclatide (NC100692 or diamine dioxime-Lys-Cys-Arg-Gly-Asp-Cyc-Phe-Cys-polyethylene glycol). Maraciclatide Tc-99m binds vitronectin receptors (αvβ3 and αvβ5 integrins) with high affinity. Maraciclatide Tc-99m is used in single-photon emission computed tomography (SPECT) imaging of vitronectin receptors that are upregulated and expressed preferentially on proliferating endothelial cells. Maraciclatide Tc-99m is being developed as a diagnostic agent to determine neoplasia and cardiovascular diseases.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. | 2005 Jun 21 |
|
| Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. | 2006 Sep |
|
| 99mTc-NC100692--a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation. | 2008 Apr |
|
| αVβ3 integrin-targeted microSPECT/CT imaging of inflamed atherosclerotic plaques in mice. | 2016 Dec |
|
| Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. | 2017 Dec |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:13:17 GMT 2023
by
admin
on
Sat Dec 16 09:13:17 GMT 2023
|
| Record UNII |
H0X34CV8RR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
H0X34CV8RR
Created by
admin on Sat Dec 16 09:13:17 GMT 2023 , Edited by admin on Sat Dec 16 09:13:17 GMT 2023
|
PRIMARY | |||
|
139033082
Created by
admin on Sat Dec 16 09:13:17 GMT 2023 , Edited by admin on Sat Dec 16 09:13:17 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
